Testing the Interplay of Gambling, Emotion and Reward

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorHôpital le Vinatier

About this trial

Background The nature and direction of dysfunctional reward processing in gambling disorder remains unclear. We aim to test a novel neurobiological model of gambling addiction, that takes into account inter-individual differences, as well as the multifactorial nature of gaming addiction.

Objectives

Primary objective:

This project will test the hypothesis that there are two opposite brain phenotypes that characterize two distinct subpopulations of gamblers, so-called impulsive vs. emotional, respectively.

Secondary objective:

This project will also seek to determine whether the brain phenotypes proposed above are capable of predicting gambling behavior outside the laboratory.

Study design The primary objective will be tested using a reward task and a facial emotion recognition task performed by participants in an fMRI scanner.

The secondary objective will be tested by combining fMRI measures with behavioral measures from everyday life collected via Ecological Momentary Assessment (EMA).

Study population This study will focus on individuals with gambling problems, as well healthy subjects with no gambling problems and no psychiatric comorbidities.

Outcomes/Endpoints

Primary endpoint:

We will compare striatum and amygdala reactivity between the three groups of impulsive gamblers, emotional gamblers and healthy subjects.

Secondary endpoint:

We will assess the correlation between emotional states and gambling behavior in everyday life, based on striatum and amygdala reactivity, using multiple linear regression models.

Eligibility criteria

Qualifiers

Aged between 18 and 65

Fluent French, read and spoken

Male and Female

Informed consent to take part in the research

Disqualifiers

Contra-indication to MRI

Protected Adults

Breast feeding or pregnant women

Neurological disorder or severe chronic illness (diabetes, heart disease, kidney disease, lung disease or liver disease, inflammatory disease….)

Trial design

Treatments tested in this trial

  • fMRI
  • Ecological Momentary Assessment

Treatment groups

120 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Hôpital le Vinatier

Lead sponsor

Institut National de la Santé Et de la Recherche Médicale, France

Collaborator